HC Wainwright Lowers Earnings Estimates for Scholar Rock

Scholar Rock Holding Corporation (NASDAQ:SRRK) – Equities research analysts at HC Wainwright cut their FY2026 earnings per share estimates for shares of Scholar Rock in a report released on Tuesday, September 15th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings per share of ($3.30) for the year, down from their prior estimate of ($3.29). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($3.23) per share. HC Wainwright also issued estimates for Scholar Rock’s FY2027 earnings at ($1.95) EPS, FY2028 earnings at ($0.59) EPS, FY2029 earnings at $0.47 EPS and FY2030 earnings at $1.44 EPS.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.84). During the same period in the prior year, the business posted ($0.98) EPS.

SRRK has been the subject of a number of other reports. Truist Financial reiterated a “buy” rating and set a $76.00 price objective (up from $55.00) on shares of Scholar Rock in a research note on Monday. BMO Capital Markets lifted their price target on shares of Scholar Rock from $76.00 to $84.00 and gave the company an “outperform” rating in a report on Monday. Wedbush reiterated an “outperform” rating and issued a $64.00 price target on shares of Scholar Rock in a research report on Tuesday. Barclays cut shares of Scholar Rock from an “overweight” rating to a “cautious” rating in a research note on Tuesday. Finally, UBS Group restated a “buy” rating on shares of Scholar Rock in a research report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $66.00.

Scholar Rock Stock Down 1.3%

NASDAQ SRRK opened at $49.37 on Thursday. Scholar Rock has a 52 week low of $27.07 and a 52 week high of $61.76. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The company has a market capitalization of $6.01 billion, a P/E ratio of -14.31 and a beta of 0.67. The stock’s 50-day moving average price is $53.22 and its 200-day moving average price is $49.62.

Insider Activity at Scholar Rock

In related news, Director Kristina Burow sold 3,053 shares of Scholar Rock stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.74, for a total transaction of $164,068.22. Following the sale, the director owned 114,657 shares of the company’s stock, valued at approximately $6,161,667.18. This trade represents a 2.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Flier sold 3,053 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $53.88, for a total value of $164,495.64. Following the completion of the transaction, the director directly owned 27,856 shares in the company, valued at approximately $1,500,881.28. This represents a 9.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 17,149 shares of company stock worth $923,108 in the last three months. Corporate insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On Scholar Rock

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SRRK. GAMMA Investing LLC grew its stake in shares of Scholar Rock by 20.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock worth $77,000 after buying an additional 242 shares in the last quarter. Values First Advisors Inc. raised its position in shares of Scholar Rock by 1.5% during the 1st quarter. Values First Advisors Inc. now owns 18,850 shares of the company’s stock valued at $927,000 after buying an additional 286 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Scholar Rock by 294.1% in the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after acquiring an additional 450 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Scholar Rock by 151.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock valued at $38,000 after acquiring an additional 525 shares during the last quarter. Finally, Syon Capital LLC grew its position in Scholar Rock by 6.4% in the second quarter. Syon Capital LLC now owns 9,782 shares of the company’s stock worth $538,000 after acquiring an additional 588 shares in the last quarter. 91.08% of the stock is owned by institutional investors.

Scholar Rock Company Profile

Scholar Rock, Inc is a biopharmaceutical company focused on developing medicines that selectively target growth factors in their latent forms. The company’s approach is designed to modulate the activation of growth factors in specific tissues, with the goal of addressing diseases in which these biological pathways contribute to impaired function or abnormal tissue growth.

Scholar Rock’s lead program is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin. The company has studied apitegromab as a potential treatment for spinal muscular atrophy, a genetic neuromuscular disorder that causes progressive muscle weakness and loss of motor function.